Allogene Therapeutics Names New CEO as Founder Steps Down
Event summary
- Dr. David Chang steps down as CEO after eight years, effective June 30, 2026.
- Dr. Zachary Roberts, current EVP of R&D and CMO, appointed as new CEO effective July 1, 2026.
- Roberts led the pivotal ALPHA3 trial in first-line large B-cell lymphoma (LBCL).
- Chang will remain on the Board of Directors.
- Roberts brings over a decade of CAR T development experience from Instil Bio and Kite Pharma.
The big picture
Allogene’s leadership transition comes as the company seeks to solidify its position in the competitive allogeneic CAR T space. The shift from founder-led to operational executive leadership reflects a strategic pivot towards scaling clinical development and expanding therapeutic applications. Roberts’ appointment underscores the importance of deep scientific and clinical expertise in navigating the next phase of growth for cell therapy.
What we're watching
- Clinical Pipeline
- Whether Roberts can sustain momentum in Allogene’s clinical programs, particularly the ALPHA3 trial in first-line LBCL.
- Strategic Vision
- How Roberts will expand the reach of allogeneic CAR T into earlier lines of therapy and new disease settings.
- Operational Execution
- The pace at which Allogene can advance its efforts into solid tumors and autoimmune disease under new leadership.
Related topics